Pre-made Modakafusp benchmark antibody ( Whole mAb Fusion, anti-ADPRC therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Modakafusp alfa (formerly TAK 573 or TEV 48573) is a CD38 targeted antibody (IgG4) fused with attenuated interferon alpha (IFN-α), being developed by Takeda, through its wholly-owned subsidiary Millennium Pharmaceuticals, for the treatment of multiple myeloma and solid tumours.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-352-1mg	1mg	Inquiry
GMP-Bios-ab-352-10mg	10mg	Inquiry
GMP-Bios-ab-352-100mg	100mg	Inquiry
GMP-Bios-ab-352-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Modakafusp biosimilar, Whole mAb Fusion: Anti-ADPRC therapeutic antibody
INN Name	Modakafusp
Target	ADPRC
Format	Whole mAb Fusion
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I/II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Takeda
Conditions Approved	na
Conditions Active	Multiple myeloma
Conditions Discontinued	na
Development Tech	na